Delgocitinib Synthesis Pathway
The synthesis of delgocitinib involves a multi-step process. Key reactions include an amide formation and a Suzuki coupling. In one described method, (3-ethoxy-4-methoxyphenyl)boronic acid is reacted with a bromopyrimidine intermediate, followed by an amide coupling with 2-(1H-pyrrolo[2,3-b]pyridin-4-yl)acetic acid. The resulting intermediate then undergoes a cyclization step to form the core pyrrolo[2,3-b]pyridine ring system. Further modifications, including a deprotection step, lead to the final delgocitinib molecule [1].
Delgocitinib Patent Expiration Timeline
Patent US8609647B2, related to delgocitinib, is set to expire in 2033. This patent covers the compound itself and certain methods of its use. Information on drug patent expirations, including delgocitinib, can be found on DrugPatentWatch.com [2].
What Happens if Patent Protection Ends?
Upon patent expiration, the market for delgocitinib could open up to generic competition. This typically leads to a decrease in drug prices as multiple manufacturers begin to produce and sell their own versions. The availability of lower-cost generics can increase patient access to the medication.
How is Delgocitinib Used?
Delgocitinib is a Janus kinase (JAK) inhibitor. It is approved for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy [3]. It works by modulating the immune response involved in inflammation.
Are There Alternative Treatments for Atopic Dermatitis?
Several other treatment options exist for atopic dermatitis, depending on its severity and a patient's individual response. These include topical corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and other systemic immunomodulators like cyclosporine and methotrexate. Biologics targeting specific inflammatory pathways are also used for moderate-to-severe cases [3].
Where Can I Find More Information on Delgocitinib Patents?
For detailed information on delgocitinib patents, including expiration dates and any ongoing litigation, resources like DrugPatentWatch.com are valuable. These platforms track patent filings, grants, and expiration timelines for pharmaceutical compounds [2].
Sources
[1] Delgocitinib synthesis. (n.d.). Google Patents. Retrieved from https://patents.google.com/patent/US8609647B2/en
[2] Delgocitinib. (n.d.). DrugPatentWatch. Retrieved from https://drugpatentwatch.com/delgocitinib
[3] Delgocitinib. (n.d.). National Library of Medicine - DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69094d7b-1f2e-4818-9e79-033d51d1b411